Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Stock Market News for September 16, 201416 Sep 2014, 7:30 amBenchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Amid Alibaba selling tsunami, Cramer finds 4 buys15 Sep 2014, 4:46 pmCramer thinks pros are so eager to buy Alibaba, they're willing to throw away perfectly good stocks. That's silly. Fortunately Cramer is smart.
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver11 Sep 2014, 7:46 amCHICAGO, Sept. 11, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CBS, IMPV, TM, CELG and NWSA.To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note:...
Why Celgene's Stock is up 11% in 201411 Sep 2014, 7:08 amWhy Celgene's Stock is up 11% in 2014
Celgene Corporation Easing Back After Run To New All-Time Highs - Is It Buyable Yet?11 Sep 2014, 6:07 amAs Celgene shares pull back off the highs after a 300 percent move over the last two years, analysts are asking if there is more upside ahead or something more unpleasant on the downside. Celgene Corporation ...
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog5 Sep 2014, 4:06 pmCelgene Corporation ( CELG ) announced the publication of impressive data on Revlimid as a combination therapy from a phase III study (FIRST n= 1,623) in patients newly diagnosed with multiple myeloma (NDMM) at the New England Journal of
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog30 Aug 2014, 8:31 amOn Aug 26, 2014, we issued an updated research report on RegeneronPharmaceuticals ( REGN ). The biopharmaceutical company reported earnings of $1.89 per share in the second quarter of 2014, missing the Zacks Consensus Estimate of $2.33 by a
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb28 Aug 2014, 6:20 amThe Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb
Biotech Stock Mailbag: Threshold, Galena, CytRx22 Aug 2014, 1:48 pmBiotech columnist Adam Feuerstein answers readers' questions about health care. Click to view a price quote on THLD . Click to research the Drugs industry.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog21 Aug 2014, 4:12 pmBristol Myers Squibb Company ( BMY ) entered into a collaboration with Celgene Corporation ( CELG ) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno oncology drug Opdivo (nivolumab, a